Patents by Inventor Esteban Masuda

Esteban Masuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
    Patent number: 7659280
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: February 9, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jeffrey Wayne Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao
  • Method for identifying compounds that modulate RXR associated processes with IgE production
    Patent number: 7604951
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 20, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • Kinase inhibitors and their uses
    Patent number: 7601713
    Abstract: The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: October 13, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Pingyu Ding, Ankush Argade, Dane Goff, Rajinder Singh, Esteban Masuda, Vanessa Taylor, Sacha Holland
  • Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
    Patent number: 7598050
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 6, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Methods and compositions for treating degenerative bone disorders
    Patent number: 7576053
    Abstract: The present disclosure provides methods and compositions using Syk inhibitory compounds for treating degenerative bone disorders and as prophylactic treatment to prevent bone loss. These treatments may reduce the fracture risk associated with bone loss and compromised bone strength.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: August 18, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Polly Pine
  • Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)
    Patent number: 7563585
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: July 21, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent number: 7538108
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds of structural formula shown below, compositions comprising these compounds, intermediates and methods for synthesizing these compounds, and methods of using these compounds in a variety of applications including treatment of autoimmune diseases.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: May 26, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Esteban Masuda, Somasekhar Bhamidipati, Thomas Sun, Valentino J. Stella
  • PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
    Publication number: 20090124580
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: November 10, 2008
    Publication date: May 14, 2009
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda
  • EDG: modulators of lymphocyte activation and migration
    Patent number: 7521192
    Abstract: The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: April 21, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: X. Charlene Liao, Esteban Masuda, Peter Chu, Jorge Pardo, Congfen Li, Haoran Zhao, Ying-Ping Jiang, Collin Spencer
  • EDG: Modulators of lymphocyte activation and migration
    Publication number: 20080260719
    Abstract: The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.
    Type: Application
    Filed: December 6, 2006
    Publication date: October 23, 2008
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: X. Charlene Liao, Esteban Masuda, Peter Chu, Jorge Pardo, Congfen Li, Haoran Zhao, Ying-Ping Jiang, Collin Spencer
  • Compounds that modulate processes associated with IgE production
    Patent number: 7425418
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: September 16, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20080221089
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: February 12, 2008
    Publication date: September 11, 2008
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
    Patent number: 7422867
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: September 9, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein
    Patent number: 7378251
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
    Patent number: 7374894
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL 4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vivo and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 20, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use
    Patent number: 7371537
    Abstract: The present invention provides compositions and methods for modulating B-lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating B-lymphocyte activation are provided. Compositions and methods for the treatment of disorders related to dysfunction or dysregulation of B-lymphocyte activation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating B-lymphocyte activation.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: May 13, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Marcy K. Vallone, Brian R. Wong, Esteban Masuda, Mark Powell
  • METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING A THIOREDOXIN-LIKE 32 KDA PROTEIN
    Publication number: 20080009076
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: December 8, 2006
    Publication date: January 10, 2008
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson
  • METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE
    Publication number: 20080003620
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: December 8, 2006
    Publication date: January 3, 2008
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson
  • METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING A B-CELL ASSOCIATED PROTEIN
    Publication number: 20080003618
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: December 8, 2006
    Publication date: January 3, 2008
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban MASUDA, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson
  • METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING A CHLORIDE INTRACELLULAR CHANNEL 1 PROTEIN
    Publication number: 20070298437
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: December 8, 2006
    Publication date: December 27, 2007
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd Kinsella, Justin Warner, Taisei Kinoshita, Mark Bennett, David Anderson